BACKGROUND: Rivastigmine enhances cholinergic activity and has been shown in clinical trials to decrease the rate of deterioration in Alzheimer's disease. It remains unclear where in the brain it exerts its effect. Functional magnetic resonance imaging (fMRI) can be used to measure changes in brain function and relate these to cognition. OBJECTIVES: To use fMRI to study brain activation with rivastigmine treatment. METHODS: The effect on brain activation of a single dose of rivastigmine was tested in seven patients with mild Alzheimer's disease using fMRI during face encoding, and in five patients during a parametric working memory task. RESULTS: During face encoding, rivastigmine increased bilateral activation in the fusiform gyrus. Brain activation was also enhanced in the prefrontal cortex in a simple working memory task. When working memory load was further increased, not only was increased activation seen, but in certain areas there was also decreased activation. CONCLUSIONS: These findings link the previously observed increase in cognitive performance in Alzheimer's disease after treatment with a cholinesterase inhibitor to altered brain activation. Although the results cannot be generalised to the Alzheimer's disease population at large, they provide evidence that in mild Alzheimer's disease, rivastigmine enhances brain activation in the fusiform and frontal cortices. This is compatible with the concept of cholinergic circuitry.
BACKGROUND:Rivastigmine enhances cholinergic activity and has been shown in clinical trials to decrease the rate of deterioration in Alzheimer's disease. It remains unclear where in the brain it exerts its effect. Functional magnetic resonance imaging (fMRI) can be used to measure changes in brain function and relate these to cognition. OBJECTIVES: To use fMRI to study brain activation with rivastigmine treatment. METHODS: The effect on brain activation of a single dose of rivastigmine was tested in seven patients with mild Alzheimer's disease using fMRI during face encoding, and in five patients during a parametric working memory task. RESULTS: During face encoding, rivastigmine increased bilateral activation in the fusiform gyrus. Brain activation was also enhanced in the prefrontal cortex in a simple working memory task. When working memory load was further increased, not only was increased activation seen, but in certain areas there was also decreased activation. CONCLUSIONS: These findings link the previously observed increase in cognitive performance in Alzheimer's disease after treatment with a cholinesterase inhibitor to altered brain activation. Although the results cannot be generalised to the Alzheimer's disease population at large, they provide evidence that in mild Alzheimer's disease, rivastigmine enhances brain activation in the fusiform and frontal cortices. This is compatible with the concept of cholinergic circuitry.
Authors: Reisa Sperling; Douglas Greve; Anders Dale; Ronald Killiany; Jennifer Holmes; H Diana Rosas; Andrew Cocchiarella; Paul Firth; Bruce Rosen; Stephen Lake; Nicholas Lange; Carol Routledge; Marilyn Albert Journal: Proc Natl Acad Sci U S A Date: 2001-12-26 Impact factor: 11.205
Authors: J V Haxby; L G Ungerleider; B Horwitz; J M Maisog; S I Rapoport; C L Grady Journal: Proc Natl Acad Sci U S A Date: 1996-01-23 Impact factor: 11.205
Authors: S Duke Han; Wes S Houston; Amy J Jak; Lisa T Eyler; Bonnie J Nagel; Adam S Fleisher; Gregory G Brown; Jody Corey-Bloom; David P Salmon; Leon J Thal; Mark W Bondi Journal: Neurobiol Aging Date: 2006-01-24 Impact factor: 4.673
Authors: Anne C Baakman; Rob Zuiker; Joop M A van Gerven; Nicholas Gross; Ronghua Yang; Michael Fetell; Ari Gershon; Yossi Gilgun-Sherki; Edward Hellriegel; Ofer Spiegelstein Journal: Br J Clin Pharmacol Date: 2019-03-14 Impact factor: 4.335
Authors: E Stefanova; A Wall; O Almkvist; A Nilsson; A Forsberg; B Långström; A Nordberg Journal: J Neural Transm (Vienna) Date: 2005-07-29 Impact factor: 3.575
Authors: Maura L Furey; Emiliano Ricciardi; Mark B Schapiro; Stanley I Rapoport; Pietro Pietrini Journal: J Cogn Neurosci Date: 2008-07 Impact factor: 3.225
Authors: Judy Pa; Anne S Berry; Mariana Compagnone; Jacqueline Boccanfuso; Ian Greenhouse; Michael T Rubens; Julene K Johnson; Adam Gazzaley Journal: Ann Neurol Date: 2013-06-17 Impact factor: 10.422
Authors: Liam Zaidel; Greg Allen; C Munro Cullum; Richard W Briggs; Linda S Hynan; Myron F Weiner; Roderick McColl; Kaundinya S Gopinath; Elizabeth McDonald; Craig D Rubin Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472